Advanced Enzyme Technologies Limited has informed the Exchange regarding approval granted for investment of Rupees 10 million in the Equity Shares of Advanced Nutrazyme Private Limited, an existing Wholly Owned Subsidiary.
ADVENZYMES · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Advanced Enzyme Technologies reported strong Q1 FY26 (quarter ended June 30, 2025) results with consolidated revenue from operations rising about 20% to ₹1,859.14 million from ₹1,545.24 million a year earlier. Consolidated net profit grew roughly 15.6% to ₹404.40 million, with EPS at ₹3.57 versus ₹3.55 last year. On a standalone basis, revenue jumped about 45% to ₹1,250.24 million and net profit rose to ₹739.81 million, helped by higher other income. The board also approved a ₹10 million cash investment in its newly incorporated wholly owned subsidiary, Advanced Nutrazyme Private Limited, which will handle sales and distribution of the company's Nutrition and Wellness range. The company also paid an interim dividend of ₹4 per share during the quarter, and shareholders approved a final dividend of ₹1.20 per share for FY25. The statutory auditor, MSKA & Associates, issued an unmodified review opinion on both sets of results.
Solid top-line growth and steady profit expansion signal healthy operating momentum, likely to be viewed positively by shareholders. The small ₹10 million infusion into a new subsidiary is a minor capital allocation move and is not material to the overall business, though it shows the company is investing in its nutrition and wellness vertical.